Abstract
Insomnia is frequently reported in children with autism spectrum disorder (ASD) and is associated with the severity of hyperactivity, irritability, sensory sensitivities, and related symptoms. The aim of this study was to examine the extent of healthcare utilization associated with insomnia in children with ASD. We conducted a retrospective, cross-sectional study of 541 children with ASD registered at the National Autism Database of Israel (NADI). Parents of all children completed the Children’s Sleep Habits Questionnaire (CSHQ) and insomnia was defined as a total CSHQ score ≥48. We compared sociodemographic characteristics, ASD diagnostic measures, chronic comorbidities, medication usage, hospitalizations, visits to the emergency room (ER), and visits to specialists between ASD children with and without insomnia. Finally, we assessed the independent association of insomnia with clinical characteristics and healthcare utilization using multivariate logistic regression models. Of the 541 children with ASD, 257 (47.5%) had insomnia. Children with insomnia compared to children without insomnia exhibited higher rates of comorbidities within the symptoms, signs, and ill-defined conditions (ICD-9[780–789]) category (aOR=1.70; 95%CI=1.04-2.77; p=0.033) and were prescribed more medications for chronic comorbidities (aOR=1.47; 95%CI=1.01-2.15; p=0.046). Finally, ASD children with insomnia were 1.75 and 2.82 times more likely to visit the ER and be hospitalized than their counterparts (aOR=1.75; 95%CI=1.17-2.62; p=0.007 and aOR=2.82; 95%CI=1.43-5.56; p=0.003, respectively). Our findings demonstrate that insomnia is associated with greater healthcare utilization among children with ASD. Thus, treating insomnia in children with ASD may have a broad clinical impact beyond specific improvements in sleep disturbances.
Introduction
Adequate sleep is essential for normal brain development in children (Ednick et al., 2009) and reduces the risk of mental health disorders (Samanta et al., 2020), hypertension (Grandner et al., 2018), cardiovascular disease (Gottlieb, Somers, Punjabi, & Winkelman, 2017), obesity, and type-2 diabetes (Reutrakul & Van Cauter, 2018) into adulthood. In contrast, insomnia, which is defined as difficulty in initiating or maintaining sleep over a sustained period of time (American Psychiatric Association & Task Force, 2013), is associated with higher usage of medications, more frequent physician visits, and twice as many hospitalizations in the general population (Léger, Guilleminault, Bader, Lévy, & Paillard, 2002).
Insomnia, identified using parent questionnaires, is reported in 40-80% of children with autism spectrum disorder (ASD) (Richdale & Schreck, 2009) in contrast to approximately 25% in typically developing children (Owens & Maski, 2016). The types of sleep disturbances reported in children with ASD include, but are not limited to, difficulties in the initiation and maintenance of sleep, restless sleep, compromised sleep quality, frequent awakenings, and a total reduction in sleep time that typically begins during the first or second year of life (Dominick, Davis, Lainhart, Tager-Flusberg, & Folstein, 2007).
Several studies have suggested that sleep disturbances in children with ASD occur due to circadian rhythm abnormalities and, more specifically, disrupted secretion of melatonin (Miano et al., 2007). Alternatively, sleep disturbances in children with ASD may be caused by disrupted sleep homeostasis such that the pressure to sleep may be reduced relative to controls (Arazi et al., 2020). Melatonin supplementation is one of the most common treatments for insomnia in ASD (Schroder et al., 2021) with several studies reporting that both immediate release (IR) and prolonged release (PR) melatonin effectively facilitate sleep initiation. PR melatonin has been shown to increase total sleep duration by up to 62 minutes while IR melatonin increases total sleep time by 40.5 minutes (Dowling et al., 2005; Ferracioli-Oda, Qawasmi, & Bloch, 2013; P. Gringras et al., 2012; Paul Gringras, Nir, Breddy, Frydman-Marom, & Findling, 2017; Maras et al., 2018).
Sleep disturbances have been associated with the presentation of additional behavioral symptoms in children with ASD. For example, several studies reported that children with ASD and insomnia also manifest higher sensory sensitivities (Cortesi, Giannotti, Ivanenko, & Johnson, 2010; Manelis-Baram et al., 2021; Tzischinsky et al., 2018) and more severe aberrant behaviors including irritability, hyperactivity, inattention, and hostility (Hollway, Aman, & Butter, 2013; Mazurek & Sohl, 2016). Shorter sleep duration has also been associated with social communication impairment and increased restricted and repetitive behaviors (RRBs) (Veatch et al., 2017). This has led to the suggestion that insomnia may exacerbate the severity of core and secondary ASD symptoms and that treating insomnia may help reduce these symptoms (Lord, 2019). Indeed, one recent study has reported that treatment with PR melatonin improved total sleep time and consequently reduced hyperactivity in children with ASD (Schroder et al., 2019).
Given the high prevalence of insomnia in children with ASD, the goal of the current study was to determine the extent of healthcare utilization associated with insomnia in children with ASD. We utilized data from the National Autism Database of Israel (NADI) at the Azrieli National Center for Autism and Neurodevelopment Research to compare the prevalence of chronic comorbidities and the amount of health service utilization between ASD children with and without insomnia.
Methods
Participants
We conducted a retrospective, cross-sectional study of 541 children with ASD, between the ages of 1-11 years old, who were registered at the NADI (Dinstein et al., 2020; Meiri et al., 2017) between 2015 and 2021. Children were included in the current study if their parents completed the Children’s Sleep Habits Questionnaire (CSHQ) and if they were members of Clalit Health Services (CHS). CHS is the largest health maintenance organization (HMO) in Israel which insures 70% of the population in the south of Israel. We focused solely on members of CHS, because the children’s electronic patient records from this HMO were available to us through the Soroka University Medical Center’s (SUMC) medical database. The study was approved by the SUMC Helsinki committee.
Evaluation of Insomnia
Sleep disturbances were evaluated using the CSHQ, a 33-item parent-rated questionnaire. The CSHQ yields scores in eight subscales relating to common types of sleep disturbances: bedtime resistance, sleep onset delay, sleep duration, anxiety around bedtime, parasomnias, night wakening, sleep-disordered breathing, and daytime sleepiness. All items are summed to create a final total score ranging between 33 and 99, with higher scores indicating greater severity. Insomnia was defined as a total sleep disturbance score ≥48, which is a conservative threshold for identifying children with severe sleep disturbances (Reynolds et al., 2019).
Evaluation of core and secondary ASD symptoms
Core ASD symptom severity was evaluated in all children using the Autism Diagnostic Observation Schedule, 2nd edition (ADOS-2) calibrated severity score (CSS). The ADOS-CSS, computed from ADOS-2 raw scores, allows comparison of ADOS-2 total scores across ages and modules (Gotham, Pickles, & Lord, 2009). We also compared DSM-5 levels of required support in the social communication (category A) and restricted, repetitive behaviors (RRB; category B) domains (American Psychiatric Association & Task Force, 2013). In addition, cognitive assessment scores from either the Bayley scales of infant and toddler development (Bayley, 2006) or the Wechsler Preschool and Primary Scale of Intelligence (WPPSI) (Wechsler, 1967) were available for most (n=445, 82%) of the children included in the final study sample.
Evaluation of Health services utilization and medication use
Health records were obtained for all participating children from the CHS electronic patient record system. We extracted all chronic comorbidities, which were coded according to the International Classification of Diseases, Ninth Revision (ICD-9) format, and grouped them into broader disease categories (excluding complications of pregnancy, childbirth, and the puerperium [630-676] and conditions originating in the perinatal period [760-799]). Records of medication usage were obtained and grouped based on primary clinical use (Supplementary Table S1). In addition, hospitalizations, visits to the emergency room, and visits to specialists during a time period corresponding to one year before and after completion of the CSHQ were also gathered from the electronic records.
Statistical Analyses
Standard univariate tests were used to examine differences in various demographic and clinical characteristics between children with ASD, with and without insomnia. Specifically, chiΔsquare or Fisher-exact tests were used to assess for differences in categorical variables, and Mann–Whitney UΔtest for continuous variables. Finally, multivariable logistic regression models were used to assess the independent association of each of these variables with insomnia, adjusted for basic sociodemographic and clinical covariates (e.g. age, sex, ethnicity, and DSM-V B required level of support). A p-value of <0.05 was considered statistically significant. The statistical analyses were performed using R studio, version 1.4.1717 (R Foundation for Statistical Computing version).
Results
Of the 1,108 children with ASD in the NADI as of August 2021, 541 children (48.9%) fulfilled the study inclusion criteria. Children included in the sample did not differ significantly from those who were not with respect to age at diagnosis, sex, ethnic origin, cognitive scores, and ADOS-2 calibrated severity scores (Table 1). Children in the study, however, required more support compared to children who were not included in the study sample, as estimated by the diagnosing physician according to the DSM-5 levels of required support. This difference may reflect a tendency of parents of children who require more support, to complete the CSHQ questionnaire.
Comparison of characteristics across children with ASD registered in the National Autism Database of Israel who met inclusion criteria for the current study versus those who did not.
Overall, participating children had a broad distribution of CSHQ scores ranging from 33 to 81, with 257 (47.5%) of them exhibiting CSHQ scores ≥ 48 indicative of insomnia (Figure 1). There were no significant differences in sex ratio, cognitive scores, or ADOS-2 calibrated severity scores across children with and without insomnia (Table 2). However, there were more children of Bedouin origin in the insomnia group (24.6% vs. 14.2%; p=0.0101) and the mean age of the children in the insomnia group was slightly higher (4.34 vs. 4.03 years; p=0.0394). In addition, children with insomnia required more support according to the DSM-V criteria with significant differences observed in the B criteria describing difficulties in RRB symptoms (p=0.0278).
Comparison of characteristics across children with and without insomnia
A histogram of the frequency of CSHQ scores (X-axis) of children with ASD in the study sample. Overall, 257 children had CSHQ scores ≥48 and were defined as having insomnia.
Abbreviations: Children’s Sleep Habits Questionnaire (CSHQ)
Chronic comorbidities
ASD Children with insomnia had significantly more comorbidities from the symptoms, signs, and ill-defined conditions classification than ASD children without insomnia (Table 3; 21.0% vs. 13.7%, P = 0.0334). There were no significant differences in other examined categories of comorbidities. There was no significant difference in number of ASD children who had comorbidities (49.8% vs. 45.8%; p = 0.3947), although those with insomnia tended to have a larger number of coexisting comorbidities than their counterparts. Notably, 19.1% of children with insomnia had three or more comorbidities, compared to only 12.7% of children without insomnia (p = 0.0414).
Comparison of chronic comorbidities between ASD children with and without insomnia
Medications use
Use of medication for the management of chronic diseases (as listed in Supplementary Table S1) for both groups is presented in Table 4. Overall, children with insomnia were more likely to be prescribed medications than children without insomnia (45.5% vs. 32.7%, P = 0.0031). This difference was partially due to prescription of medication for insomnia (e.g., Melatonin and Promethazine) that was almost twice more frequent in the insomnia group (15.2% vs. 8.1%, P=0.0145). Nevertheless, the amount of prescribed medications for children with ASD and insomnia was still significantly higher after excluding medications that treat insomnia (37.0% vs. 28.2%, P = 0.0364), demonstrating that they use more medications that are unrelated to sleep. In particular, prescription for medications in the treatment of mental or mood conditions were significantly more frequent in the insomnia group (9.7% vs. 4.9%, P = 0.0468).
Comparison of medication usage between children with and without insomnia
Health services utilization
Children with ASD and insomnia utilized more health services than children without insomnia (Figure 2) including 50% more visits to the emergency room (mean[SD] = 0.63[1.19] vs. 0.42[1.01]; p= 0.0153) and a 2.7 times higher rate of hospitalization (mean[SD] = 0.19[0.60] vs. 0.07[1.30]; p= 0.0042). Consequently, children with insomnia were hospitalized for twice the number of days compared to children without insomnia (mean[SD] = 0.32[1.08] vs. 0.16[1.06] days per child respectively; p= 0.004). These findings suggest that the cost of emergency room visits and hospitalization is significantly higher for children with insomnia. No significant differences were found in the total number of outpatient visits, including visits to primary care physicians (mean[SD] = 16.7 [14.7] vs. 16.9 [13.2] visits per child respectively; p= 0.7492) and specialists (mean[SD] = 0.95[1.81] vs. 0.80[1.51] visits per child respectively; p= 0.5206).
A. Number of hospitalizations. B. Days hospitalized. C. Number of visits to a specialist. D. Number of visits to a primary care physician. E. Number of visits to the emergency room. Note that percentages presented in panels A, C and E sum to 13.6%, 42.4% and 34.6% of ASD children with insomnia and 6.4%, 58.5% and 25.3% of children without insomnia who were hospitalized, visited specialists, and who visited the emergency room, respectively. P-values from Mann-Whitney U tests are for the differences between children with and without insomnia.
Abbreviations: Children’s Sleep Habits Questionnaire (CSHQ), Emergency room (ER),
Factors associated with insomnia
Finally, we used multivariable logistic regression models, to quantify the independent association of factors associated with insomnia in our sample while controlling for potential confounders (Table 5). Insomnia in children with ASD was significantly associated with a 1.70 higher likelihood of having a comorbidity within the symptoms, signs, and ill-defined conditions classification (aOR = 1.70; 95% CI = 1.04, 2.77; p=0.033) and a 1.47 higher likelihood of medication use (aOR = 1.47; 95% CI = 1.01, 2.15; p=0.046). In addition, insomnia in children with ASD was also significantly associated with visits to the emergency room (≥1 visits during the study period) (aOR = 1.75; 95% CI = 1.17, 2.62; p=0.007), and hospitalizations (≥1 hospitalizations during the study period) (aOR = 2.82; 95% CI = 1.43, 5.56; p=0.003). No other health services factors were associated with insomnia in children with ASD after accounting for confounders.
Factors associated with insomnia in children with ASD.
Discussion
This study examined the health burden associated with insomnia among children with ASD. The findings show that insomnia is present in nearly 50% of children with ASD and that these children have a higher number of comorbidities, use more medications for the management of chronic diseases, and are more likely to visit the emergency room and be hospitalized compared to children with ASD without insomnia. Altogether, these results suggest that insomnia is associated with a greater clinical and economic burden among children with ASD.
These findings from children with ASD are in line with previous studies that have reported positive associations between insomnia and a diverse range of comorbidities within the general adult population. These include associations between insomnia and anxiety and depression (Sørensen, Jensen, Rathleff, & Holden, 2019), gastrointestinal disorders (Balikji et al., 2018), psychopathy symptoms (Akram et al., 2018), and even a 45% increased risk of mortality from cardiovascular disease (Sofi et al., 2014). Some studies have proposed possible mechanistic explanations for the increased presence of comorbid disorders in individuals with insomnia including circadian rhythm misalignment (Nobre, Rocha, Morin, & Meira e Cruz, 2021), a low-grade inflammatory state (Friedman, 2011), elevation of cortisol (Vargas et al., 2018), and metabolic or endocrine changes (Copinschi, 2005). Some of these mechanisms were also suggested to be involved in ASD etiology (Abdul et al., 2022; Geoffray, Nicolas, Speranza, & Georgieff, 2016), thus highlighting potential mechanistic links between ASD and insomnia.
The association of insomnia with greater use of health services in this study is also consistent with previous reports of increased utilization of health services in adults with insomnia in the general population including more frequent emergency room visits and hospitalizations, but no significant increases in the number of physician visits (Léger et al., 2002; Skaer & Sclar, 2010). Moreover, in our study insomnia remained an independent predictor of healthcare utilization in ASD children even after controlling for the number of comorbidities in these children.
Finally, individuals with insomnia in the general population were also reported to consume more medications than good sleepers, especially, sleep medications, sedatives, anti-depressants, pain relief medications, asthma medications, and cardiac medications (Daley et al., 2009; Sivertsen, Krokstad, Mykletun, & Øverland, 2009). These results are also consistent with this study’s findings of higher overall medication use among ASD children with insomnia. Notably, in the current study, medications use for mental and mood conditions were also associated with insomnia in the unadjusted models. This finding is expected given that ASD children with insomnia display more aberrant behaviors (Hollway et al., 2013; Mazurek & Sohl, 2016), and antipsychotics, including risperidone and aripiprazole (the two most common medications prescribed in this study sample under the mental and mood conditions classification), are prescribed to reduce disruptive behaviors, particularly irritability and aggression in children with ASD (Ching & Pringsheim, 2012; Loy, Merry, Hetrick, & Stasiak, 2017). The higher rate of insomnia among children who are prescribed drugs for mental and mood conditions could be due to the known side effects of these drugs in causing sleep problems (Miller & McCall, 2022), however, the association of these drugs in our study were mild and not statistically significant (p = 0.220).
The results reported in this study should be interpreted in the context of the following limitations. First, information on the child’s sleep behavior was gathered via parental reports using the CSHQ. This method may be biased as it relies on parent impressions and their subjective ability to accurately recall their child’s sleep habits. Alternative methods such as daily sleep diaries or direct measures such as actigraphy and polysomnography may offer less biased estimates of sleep disturbances, however, these measures are often difficult to acquire from children with ASD due to sensory sensitivities and lack of cooperation (Goldman et al., 2009). Second, this study used a retrospective, cross-sectional design and thus it was not possible to determine causality or directionality of the association between the emergence of insomnia and utilization of health services. Lastly, data was obtained solely from the electronic records, which included only clinical data, and no information was obtained about use of unprescribed or over-the-counter medications, including melatonin.
Conclusions
Our findings demonstrate that insomnia is significantly associated with greater healthcare utilization among children with ASD. First-line recommendations for insomnia treatment include a wide-range of behavioral interventions that can reduce sleep difficulties and improve sleep quality for some children with insomnia (Guénolé et al., 2011; Rossignol & Frye, 2011). In children with ASD, insomnia can be treated with behavioral interventions and then supplemented with pharmacological treatment (Schroder et al., 2021). Thus, future prospective follow-up studies could examine whether successful treatment of insomnia reduces health services utilization and comorbid disorders in ASD children. This would be critical for revealing whether insomnia treatments have a broad clinical impact beyond the reduction of sleep disturbances.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Financial Disclosure
This study was funded by Neurim Pharmaceuticals Ltd.
Conflict of Interest Disclosure
None.
Acknowledgements
We thank the families who participated in this research.
References
